SCHEDULE 13G: Armistice Capital and Steven Boyd Disclose 9.99% Stake in Helius Medical Technologies
Beneficial Ownership Report
Investment firm Armistice Capital, LLC and its managing member Steven Boyd have disclosed a beneficial ownership of 9.99% in Helius Medical Technologies, Inc.'s Class A Common Stock.
Summary
- Armistice Capital, LLC and Steven Boyd, collectively referred to as the 'Reporting Persons', have filed a Schedule 13G indicating beneficial ownership in Helius Medical Technologies, Inc.
- The filing reports that the Reporting Persons beneficially own 871,134 shares of Helius Medical Technologies, Inc.'s Class A Common Stock.
- This ownership represents 9.99% of the total outstanding Class A Common Stock.
- The shares are held with shared voting power and shared dispositive power by both Armistice Capital, LLC and Steven Boyd.
- Armistice Capital, LLC is identified as an investment adviser (IA) and other (OO) type of reporting person, while Steven Boyd is identified as a parent holding company (HC) and individual (IN).
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or outlook. It is a neutral regulatory filing.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of a significant ownership stake by an investment firm and its principal, common in the financial industry for transparency regarding large holdings in publicly traded companies. It reflects an investment decision by Armistice Capital in the medical technology sector.
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by an institutional investor like Armistice Capital may be viewed positively by other shareholders, potentially signaling confidence in the company's prospects. It also provides transparency regarding major ownership positions.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires the filing of this statement |
| 05/15/2025 | Date of filing of the Schedule 13G statement |
Keywords
Helius Medical Technologies, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Class A Common Stock, Investment Adviser, SEC Filing, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.